Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide

• Status: Recruiting
• Trial end date: 2022-05-30
• Target enrollment: 0
• Participant gender: Female

Summary

Postpartum prophylactic HCTZ administration for prevention and relapse of preeclampsia or gestational hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Medical Branch, Galveston
• Treatments: Hydrochlorothiazide

Criteria

Inclusion Criteria:

• Maternal age ≥ 18 years and <50 years.

• Diagnosis of gestational hypertension* or preeclampsia^ at any time during pregnancy, labor or postpartum.

• defined as isolated systolic BP of 140 mm Hg or greater, a diastolic BP of 90 mm Hg or greater, or both) or ^ defines as new-onset hypertension plus new-onset proteinuria, or in the absence of proteinuria, preeclampsia is diagnosed as hypertension in association with thrombocytopenia (platelet count less than 100,000/microliter), impaired liver function (elevated blood levels of liver transaminases to twice the normal concentration), the new development of renal insufficiency (elevated serum creatinine greater than 1.1 mg/dL or a doubling of serum creatinine in the absence of other renal disease), pulmonary edema, or new-onset cerebral or visual disturbances.)

Exclusion Criteria:

• Subject requiring antihypertensive therapy at time of screening.

• Planned discharge with oral anti-hypertensive medication.

• Contraindication to hydrochlorothiazide (advanced renal failure or anuria, hypersensitivity to sulfonamides).

• Subject not able to follow up postpartum.

• Lactose intolerance.

• Pre-gestational diabetes.